Abstract

The aim of the present study was to evaluate the anesthetic and cardiopulmonary effects of dexmedetomidine in combination with tiletamine (without zolazepam) as a general anesthetic. The study was divided into two phases. In Phase 1, 18 adult healthy mixed-breed dogs were randomly allocated into three groups: Group TD8 (4.5 mg kg−1 tiletamine and 8 μg kg−1 dexmedetomidine), Group TD10 (4.5 mg kg−1 tiletamine and 10 μg kg−1 dexmedetomidine), or Group TD12 (4.5 mg kg−1 tiletamine and 12 μg kg−1 dexmedetomidine). After drug administration, the heart rate (HR), respiratory rate (f R), mean arterial pressure (MAP), systolic arterial pressure (SAP), diastolic arterial pressure (DAP), peripheral hemoglobin oxygen saturation (SpO2), behavioral score, quality of induction and recovery, extent of ataxia, the time taken for induction, and the duration of anesthesia were recorded. The recovery time and quality were recorded after administration of atipamezole (50 μg kg−1) after 60 min. In phase 2, the feasibility of combining dexmedetomidine (10 μg kg−1) and tiletamine (4.5 mg kg−1) as general anesthetics for orchiectomy was evaluated in dogs (n = 6). HR, f R, MAP, SAP, DAP, temperature, SpO2, behavioral scores, and adverse reactions were recorded during each surgical procedure. In phase 1, the dogs were anesthetized for 5 min after administration of drugs and achieved a maximum behavioral score in TD10 and TD12 after 10 min. Although HR, MAP, SAP, DAP, and NIBP decreased in all three groups, they still maintained within the normal range. In phase 2, orchiectomy was completed smoothly in all dogs with little fluctuation in the physiological variables. We found that a combination of tiletamine (4.5 mg kg−1) and dexmedetomidine (10 μg kg−1) intramuscularly induced moderate anesthesia in dogs and could be utilized for short-term anesthesia and minor surgery.

Highlights

  • Dexmedetomidine is a highly selective α2 adrenergic agonist that acts as a sedative and analgesic, with anti-anxiety properties

  • It has been observed that dexmedetomidine–butorphanol–tiletamine– zolazepam (DBTZ) administered intramuscularly (IM) in healthy dogs rapidly induced short-term anesthesia and analgesia [7]

  • In phase 2, we evaluated the feasibility of combining dexmedetomidine and tiletamine as a general anesthetic for orchiectomy in dogs

Read more

Summary

Introduction

Dexmedetomidine is a highly selective α2 adrenergic agonist that acts as a sedative and analgesic, with anti-anxiety properties. Tiletamine is a competitive N-methyl-D-aspartic acid (NMDA) receptor antagonist that exhibits a dissociative anesthetic effect [4]. It is highly species-specific and can induce analgesia and is a general anesthetic in mice, rats, pigeons, cats, and monkeys. Tiletamine can cause depression in guinea pigs and rabbits [5, 6] It is usually provided with zolazepam in veterinary settings as a narcotic sedative (tiletamine/zolazepam or Zoletil R ) for use as a shortterm anesthetic for surgical procedures in dogs [7,8,9]. It has been observed that dexmedetomidine–butorphanol–tiletamine– zolazepam (DBTZ) administered intramuscularly (IM) in healthy dogs rapidly induced short-term anesthesia and analgesia [7]

Objectives
Methods
Results
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call